Lakefront Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lakefront Biotherapeutics (LKFT).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingEqual-Weight# Analysts1Avg. Consensus PT$36Upside to Avg. PT+4.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	RBC Capital	Brian Abrahams	Upgrade	Sector Perform→Outperform	$26→$45
Aug 11, 2026	Morgan Stanley	Judah Frommer	PT Cut	Equal-Weight	$30→$26
Aug 11, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$28→$26

Analyst Ratings News

This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.

Avi Kapoor

PRO
RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26

RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.

Benzinga Newsdesk

Lakefront Biotherapeutics NV

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Lakefront Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

PRO
RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

PRO
Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

PRO
RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

Lakefront Biotherapeutics NV

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Lakefront Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

PRORBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

PROMorgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

PRORBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

PRO
RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

PRO
Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

PRO
RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26